<DOC>
	<DOCNO>NCT02577783</DOCNO>
	<brief_summary>The purpose study determine whether doxorubicin hydrochloride liposome superior doxorubicin combine bortizomib dexamethasone treat patient initially diagnose multiple myeloma .</brief_summary>
	<brief_title>PDD v PAD Treat Initially Diagnosed MM</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Newly diagnose untreated multiple myeloma patient Patients age 18 70 year With evaluable disease ECOG score ≤2 NE≥1.0×10E9 /L , Plt≥50×10E9 /L , Hb≥70 g/L AST , ALT , ALP≤3×ULN , serum BIL≤ULN LVEF≥ 50 % Not pregnancy Written inform consent acquire Severe heart failure ( NYHA grade II high ) Active uncontrolled severe infection HIV positive Have accept antitumor drug within 30 day first dose doxorubicin hydrochloride iposome doxorubicin Grade 2 high peripheral neuropathy treatment Have suffer malignancy past 5 year Females lactation Other situation investigator consider contraindication study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Doxorubicin Hydrochloride</keyword>
</DOC>